Agno Insights and Resources

Agno Pharma’s Particle Sciences Achieves ISO 13485:2016 Certification

How Agno Pharma Ensures RSM and Intermediates Excellence: A Behind-the-Scenes Look

2025 Trends in Pharmaceutical Analytical Methods Development & Validation

2025 Trends in Pharmaceutical Drug Product Manufacturing

Behind the Scenes: Agno Pharmaceuticals’ Visit to Our State-of-the-Art Biotech Manufacturing Facilities in China

Who is Agno Pharmaceuticals?

Guide to Inhalation and Respiratory Aerosol Drug Delivery: Leveraging CDMO Expertise

Complete Guide to Pre-Clinical Drug Product Manufacturing

The Guide to Cryomilling and Refining Polymer Powders

Meet the Machine: The Bausch 515 Aseptic Filling & Closing Machine

What to Expect From Your Nanomilling Partner or Company

How to Enhance the Solubility of Ocular Drug Products

How to Select the Right CDMO for Your Sterile Drug Product in 2023

Solving Bioavailability Challenges Using A Drug Product’s Target Product Profile (TPP)

Bridging Clinical and Commercial Drug Product Manufacturing – Outsourcing Advice from a CDMO

Ocular Implants for Drug Delivery: Improving Patient Outcomes

Nasal Drug Formulation: A Guide to Successful Drug Product Development

A Guide to Drug Development for Biologics: Overcoming Formulation and Manufacturing Challenges

2024 Pharma Trends Shaping the CDMO Industry Outlook

Phase Appropriate Filter Validation for Sterile Drug Product Manufacturing

Filter Validation: Key Elements for Sterile Drug Product Manufacturing

A 2024 Guide to Solubility Improvement and Bioavailability Enhancement Techniques

A Pharmaceutical Guide to Cannabis – FAQs for Drug Product Development

A 2023 Guide to Vaccine Development & Immunization

The Guide to Analytical Method Development

Targeted Therapeutics and Nanoparticles

Key Takeaways From the FDA Complex Generic Drug Product Development Workshop: Part 2

Key Takeaways From the FDA Complex Generic Drug Product Development Workshop: Part 1

Considerations in Particle Sizing – Part 1: Classification of the Various Sizing Techniques

Code of Federal Regulations Title 21 Part 11 Requirements

In Vitro Dissolution Testing For Solid Oral Dosage Forms

How Personalized Medicine is Evolving the CDMO Landscape

Physical Stability of Disperse Systems

Drug Substance Solid State Characterization

Biopharmaceutical Classification System

Solid Lipid Nanoparticles

Glossary of Nanotech

Quality by Design

Process Analytical Technology

Phase Behavior of Surface-Active Solutes

Cubic Phase Particles

Solid Solutions and Dispersions

Overview of the Zeta Potential

Nanotechnology – New Name – Old Science

Solubility – Ideal Solubility & Solubility Models

Sampling of Powders

Potent Compound Handling Operations

Hot Melt Extrusion

Emulsion Stability and Testing

Glossary of Polymer Terms

Encapsulation

Mechanical Dispersing of Insoluble APIs

Dissolution Testing for OSD

The Patent Process

Dissolving Films

Combination Devices

Surfactants

Development and Validation of In Vitro Release Testing for Semisolid Formulations

Emulsions and Emulsifications

Protein Structure: Primary, Secondary, Tertiary, Quatemary Structures

Considerations in Particle Sizing – Part 2: Specifying a Particle Size Analyzer

Analytical Method Development and Validation

Mass Spectrometry in Bioanalysis

Skin and Nail: Barrier Function, Structure, and Anatomy Considerations for Drug Delivery

Particle Size Distribution and Its Measurement

Lyophilization of Pharmaceuticals: An Overview

Orphan Drug Product Development: Incentives and Outsourcing Considerations

Understanding Analytical Method Validation with Laurie Goldman

The FDA’s Recent Uptick in Ophthalmic NDA & BLA Approvals

Overcoming Solubility Challenges: Techniques to Improve Dissolution Rate and Increase Bioavailability

Highly Potent API (HPAPI) Handling: An Expert Interview with Judy Cohen

Aseptic Manufacturing and Sterile Fill-Finish for Complex Drug Products

6 Takeaways from the FDA’s Complex Generic Drug Product Development Workshop

Hot Melt Extrusion: Solubility Enhancement, Controlled Release, and More

Why the FDA Loves Complex Generic Drug Products

Nanomilling: A Key Option for Formulating Water-Insoluble APIs

What are Complex Drug Products and Why Should You Care?